Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome

Hypermobile Ehlers-Danlos Syndrome: Efficacy of Non-invasive Vagal Nerve Stimulation and Effects on Brain-Gut Physiology

Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS is associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS). This study will address the clinical relationship between hEDS/Hypermobile Spectrum Disorders and autonomic regulation and see if there is a benefit of two forms of non-invasive vagal nerve stimulation therapies to reduce GI symptoms in hEDS and POTS. The study will also investigate plausible effects of these nerve stimulation therapies on gastric function and autonomic signaling.

Study Overview

• Status: Recruiting
• Conditions: Functional Gastrointestinal Disorders; Postural Orthostatic Tachycardia Syndrome; Hypermobile Ehlers-Danlos Syndrome; Autonomic Nervous System Disease; Autonomic Nervous System Imbalance
• Intervention / Treatment: Other: Acoustic vagal nerve stimulation (aVNS) treatment; Device: Percutaneous vagal nerve stimulation (pVNS) device

Detailed Description

Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS and Hypermobile Spectrum Disorders are associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS). Symptoms are often disabling and associated with poor quality of life and high health care costs. The proposed research will address the following understudied areas: 1) the clinical relationship between hEDS and autonomic regulation, 2) the potential benefit of two forms of non-invasive vagal nerve stimulation (VNS) therapies in reducing functional GI symptoms in hEDS and POTS, and 3) plausible effects of these VNS therapies on gastric motor function and neurohormonal signaling.

Clinical reports document a high co-morbidity between autonomic disorders and hEDS. This prospective study will focus on three major clinical questions: 1) Are there reliable neurophysiological markers associated with hEDS that can provide insights into the 'neural mechanisms' resulting in multisystem co-morbidities? 2) Will innovative intervention techniques designed to enhance autonomic regulation via two non-invasive vagal nerve stimulation techniques (e.g., auricular and acoustic VNS) provide substantial symptom reduction and improve the hEDS patients' quality of life? 3) Can a novel gastric MRI technique capture gastric motor function abnormalities in adolescents with hEDS?

• Study Type: Interventional
• Enrollment (Anticipated): 90
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Katja Kovacic, MD; Phone Number: (414) 266-3690; Email: kkovacic@mcw.edu
• Study Contact Backup: Name: Monica Grimm, BA; Phone Number: (414) 266-6111; Email: mgrimm@mcw.edu

Study Locations

• United States
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Recruiting
      • Medical College of Wisconsin
      • Contact: Monica Grimm, BA; Phone Number: 414-266-6111; Email: mgrimm@mcw.edu
      • Principal Investigator: Katja Kovacic, MD
      • Sub-Investigator: Donald Basel, MD
      • Sub-Investigator: Matthew Plunk, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 10 years to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Children aged 10-18 years old
• Children with functional upper GI complaints and clinical suspicion for hEDS or HSD as well as a Beighton score of at least 4/9
• Children with functional upper GI complaints and clinical suspicion for ANS dysfunction
• De-identified data from our prior studies (IRB #689519 and IRB #1064187) of patients with functional GI disorders who do NOT meet criteria for hEDS will be used as a comparison group
• Children who are English-speaking and lack other explanation for symptoms
• Children willing to participate and consent to this study (for children, have a parent willing to participate)

Exclusion Criteria:

A) Exclusion Criteria applying to all participants:

• Medically complex children or those who take a medication or suffer from a disease that can explain symptoms will be excluded from participation in the study.
• Adult subjects, children or their parents who have significant developmental delay (will be excluded due to difficulties in accurately completing the questionnaires and assessing symptoms)
• Patients with findings of organic disease such as peptic ulcer disease, H.pylori gastritis, celiac disease, inflammatory bowel disease, allergic disorders, metabolic disorder or any other chronic condition or medication that may cause chronic GI symptoms will be excluded from the study.
• Patients who are treated with a new drug affecting the central nervous system in the two weeks prior to enrollment will also be excluded.
• Pregnancy (evaluating MD screens patients as they normally would during a clinic visit (by questioning) and would only perform urine pregnancy test if clinically indicated (absence of menstrual period or other symptoms concerning for pregnancy)
• Chronic alcohol/illicit drug use and/or smoking.

B) Exclusion Criteria for subjects undergoing pVNS therapy:

• Severe dermatological condition or active infection of external or middle ear
• Implanted electrical device

C) Exclusion Criteria for subjects undergoing aVNS therapy:

• Hearing impaired
• Sight impaired without correction
• Seizure disorder

D) Exclusion Criteria for subjects undergoing gastric motor function sub-study:

• Patients with pacemakers, metal clips used in previous surgery or other device which are not compatible with MRI scanning
• Claustrophobia or inability to lie still in the scanner
• Orthodontic braces or permanent retainers
• Patients who are unable to tolerate noise produced by the MRI
• Egg allergy or anticipated inability to complete a standardized egg meal

E) Exclusion Criteria for subjects undergoing HepGI Biobank specimen collection sub-study:

• Bleeding disorder for the specific biopsies
• Recent antibiotic usage for fecal sample
• Significant anemia or clinical status which will not allow safe blood draw required for blood collection
• Refusal of blood collection or to provide DNA sample
• Inability or unwillingness on the individual (or parent/legal guardian) to provide clinical or family history.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Treatment Arm A (hEDS); (n=60) patients who meet criteria for hEDS or Hypermobile Spectrum Disorder (HSD) will receive aVNS (acoustic vagal nerve stimulation) therapy via filtered vocal music sound therapy using the Safe and Sound protocol (randomized 1:1 to active vs sham music; double blind study design)	Other: Acoustic vagal nerve stimulation (aVNS) treatment; All subjects receiving acoustic therapy via active VNS (aVNS; n=30) or sham VNS (sVNS; n=30) will enter a four-week, randomized, double-blind clinical trial during which they will listen to either computer altered/filtered vocal music (active treatment) that has been designed to stimulate vagal calming vs. regular non-filtered music (sham treatment). The stimuli will mirror the acoustic intervention known as the Safe and Sound Protocol. This protocol has been found to reduce auditory hypersensitivities and calming the autonomic nervous system by increasing vagal regulation of the heart via brainstem ventral vagal complex. The acoustic intervention may be played by an electronic device (i.e. smartphone, tablet, laptop, mp3) and delivered virtually with the help of trained coaches.; Other Names: Safe and Sound Protocol
Experimental: Treatment Arm B (ANS Dysfunction); (n=30) patients with concerns for ANS dysfunction (with or without hEDS) will receive auricular percutaneous vagal nerve stimulation (pVNS) therapy. Additional sub-study option: 15-20 subjects will undergo gastric MRI and (those who consent to it) will also participate in a biobank blood sample collection study.	Device: Percutaneous vagal nerve stimulation (pVNS) device; Subjects in Treatment Arm B will enter a six-week, prospective open label treatment trial with the FDA-approved and commercially available device IB-Stim. This is an ambulatory, neurostimulation device which consists of a battery powered, externally affixed generator with 4 wire leads attached to electrode/needle arrays affixed to the outer ear. The device delivers low voltage (3.2V) stimulation in alternating frequencies for a total of 5 days (around the clock).; Other Names: percutaneous electrical nerve field stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in gastrointestinal symptoms as assessed by the instrument Patient Assessment of upper Gastrointestinal Symptom Severity Index (PAGI-SYM)	Instrument assessing upper gastrointestinal symptoms including symptoms of gastroparesis; score range 0-100 with higher scores indicating worse symptoms	Change from baseline total PAGI-SYM score at end of therapy (6 weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in gastric motility function as assessed by gastric MRI motility index	Dynamic gastric MRI measure of gastric contractility as measured by motility index generated by GIQuant software motility index; score range 100-700 with lower scores indicating worse gastric motility	Change from baseline at end of therapy (6 weeks)
Change in Body Perception Questionnaire (BPQ) total score	Instrument assessing symptoms of autonomic reactivity; raw score range 0-130 with higher score indicating greater autonomic reactivity	Change from baseline at end of therapy (6 weeks)
Change in vagal efficiency measurements	Metrics of vagal tone extracted from ECG R-R interval data measurements during postural challenges	Change from baseline at end of therapy (6 weeks)
Change in respiratory sinus arrhythmia measurements	Metrics of vagal tone extracted from ECG R-R interval data measurements during postural challenges	Change from baseline at end of therapy (6 weeks)

Collaborators and Investigators

• Sponsor: Medical College of Wisconsin
• Collaborators: University College, London; Indiana University

Publications and helpful links

General Publications

• Kovacic K, Hainsworth K, Sood M, Chelimsky G, Unteutsch R, Nugent M, Simpson P, Miranda A. Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomised, double-blind, sham-controlled trial. Lancet Gastroenterol Hepatol. 2017 Oct;2(10):727-737. doi: 10.1016/S2468-1253(17)30253-4. Epub 2017 Aug 18.
• Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):148-157. doi: 10.1002/ajmg.c.31539. Epub 2017 Feb 1.
• Kovacic K, Chelimsky TC, Sood MR, Simpson P, Nugent M, Chelimsky G. Joint hypermobility: a common association with complex functional gastrointestinal disorders. J Pediatr. 2014 Nov;165(5):973-8. doi: 10.1016/j.jpeds.2014.07.021. Epub 2014 Aug 20.
• Gazit Y, Nahir AM, Grahame R, Jacob G. Dysautonomia in the joint hypermobility syndrome. Am J Med. 2003 Jul;115(1):33-40. doi: 10.1016/s0002-9343(03)00235-3.
• Porges SW, Davila MI, Lewis GF, Kolacz J, Okonmah-Obazee S, Hane AA, Kwon KY, Ludwig RJ, Myers MM, Welch MG. Autonomic regulation of preterm infants is enhanced by Family Nurture Intervention. Dev Psychobiol. 2019 Sep;61(6):942-952. doi: 10.1002/dev.21841. Epub 2019 Mar 13.

Study record dates

Study Major Dates

• Study Start (Actual): April 5, 2021
• Primary Completion (Anticipated): December 31, 2023
• Study Completion (Anticipated): December 31, 2023

Study Registration Dates

• First Submitted: November 2, 2021
• First Submitted That Met QC Criteria: January 26, 2022
• First Posted (Actual): January 27, 2022

Study Record Updates

• Last Update Posted (Actual): February 24, 2023
• Last Update Submitted That Met QC Criteria: February 22, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Skin Diseases; Disease; Congenital Abnormalities; Hematologic Diseases; Hemorrhagic Disorders; Genetic Diseases, Inborn; Connective Tissue Diseases; Hemostatic Disorders; Skin Diseases, Genetic; Arrhythmias, Cardiac; Cardiac Conduction System Disease; Skin Abnormalities; Orthostatic Intolerance; Collagen Diseases; Syndrome; Nervous System Diseases; Gastrointestinal Diseases; Digestive System Diseases; Tachycardia; Postural Orthostatic Tachycardia Syndrome; Primary Dysautonomias; Autonomic Nervous System Diseases; Ehlers-Danlos Syndrome
• Other Study ID Numbers: 1541191

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No